Premium
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients...
Inventiva fait un point sur ses activités et publie ses résultats financiers non audités du premier semestre 2024 Le recrutement dans l'étude clinique NATiV3 progresse, avec plus de 85 % du nombre...
Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95...
Inventiva publie ses informations financières préliminaires du premier semestre 2024¹ Trésorerie et équivalents de trésorerie à 10,1 millions d’euros au 30 juin 2024, contre 26,9 millions d’euros...
Inventiva Reports Preliminary 2024 First-Half Financial Information¹ Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.012...
Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.012 million of short-term deposits and €9.03 million of long-term...
Inventiva obtient un nouveau brevet au Japon, élargissant la protection de la propriété intellectuelle de lanifibranor ► L'Office des brevets japonais a accordé la demande de brevet d'Inventiva...
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor Japanese Patent Office approved Inventiva’s patent application relating to the use...
Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis.1This patent strengthens Inventiva’s intellectual property with...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.146 | -8.58823529412 | 1.7 | 1.7 | 1.552 | 33827 | 1.66145596 | DE |
| 4 | -0.556 | -26.3507109005 | 2.11 | 2.11 | 1.51 | 32253 | 1.78466726 | DE |
| 12 | -1.006 | -39.296875 | 2.56 | 2.715 | 1.51 | 28482 | 2.09472 | DE |
| 26 | -1.826 | -54.0236686391 | 3.38 | 3.67 | 1.51 | 32734 | 2.66722663 | DE |
| 52 | -2.441 | -61.1013767209 | 3.995 | 4.44 | 1.51 | 44556 | 3.22975534 | DE |
| 156 | -10.146 | -86.7179487179 | 11.7 | 13 | 1.51 | 52816 | 4.28899423 | DE |
| 260 | -0.606 | -28.0555555556 | 2.16 | 16.16 | 1.51 | 65089 | 7.03548159 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
